Single Dose Escalation of PHIN-214 in Child-Pugh A Liver Cirrhotics
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This single ascending dose (SAD) study evaluates PHIN-214, being studied to determine the
safety, tolerability, and pharmacokinetics, and establish the maximum tolerated dose of this
compound in patients with compensated cirrhosis.